A phase 2b trial has been conducted on aleniglipron, an oral small molecule GLP-1 receptor agonist, in people with overweight or obesity. The trial results reportedly show significant weight loss, with one outlet citing up to 12% weight loss in 36 weeks, although the details of the outcomes are not universally agreed upon. The results have been released by Structure Therapeutics Inc. and presented at a scientific conference, with some outlets noting the positive data and its implications for future trials.